Erratum: Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth (PLoS Pathogens (2016) 12:3 (e1005472) DOI: 10.1371/journal.ppat.1005472);Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth

PLoS Pathogens

Volumn 12, Issue 3, 2016, Pages

  Kiselinova, Maja ^a,b   De Spiegelaere, Ward ^a   Buzon, Maria Jose ^b,c   Malatinkova, Eva ^a   Lichterfeld, Mathias ^b,c,d   Vandekerckhove, Linos ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' DEAMINO 3' MORPHOLINOOXAUNOMYCIN; PSIP1; SAMHD1; SLFN11; TRANSCRIPTION FACTOR; TRIPARTITE MOTIF PROTEIN 5; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; GENE DOSAGE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TEST RETEST RELIABILITY; VIROGENESIS; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION; COHORT ANALYSIS; DISEASE CARRIER; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ISOLATION AND PURIFICATION; STATISTICAL MODEL; VIROLOGY; VIRUS DNA CELL DNA INTERACTION;

ADULT; COHORT STUDIES; DISEASE RESERVOIRS; DNA, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; RNA, VIRAL; VIRAL LOAD; VIRUS INTEGRATION;

EID: 84962423885     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1005532     Document Type: Erratum

References (46)

1. Perelson AS, Essunger P, Cao YZ, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997;387(6629):188–91. doi: 10.1038/387188a0WOS:A1997WX94500056.
2. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nature medicine. 1999;5(5):512–7. doi: 10.1038/839410229227.
3. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF, In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nature medicine. 1995;1(12):1284–90. 7489410.
4. Archin NM, Margolis DM, Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis. 2014;27(1):29–35. doi: 10.1097/Qco.0000000000000026WOS:000329188700004.
5. Bruner KM, Hosmane NN, Siliciano RF, Towards an HIV-1 cure: measuring the latent reservoir. Trends in microbiology. 2015;23(4):192–203. doi: 10.1016/j.tim.2015.01.01325747663.
6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+T cells. Nature medicine. 2003;9(6):727–8. doi: 10.1038/nm88012754504.
7. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DIS, et al. Replication-Competent Noninduced Proviruses in the Latent Reservoir Increase Barrier to HIV-1Cure. Cell. 2013;155(3):540–51. doi: 10.1016/j.cell.2013.09.020WOS:000326571800010.
8. Lewin SR, Rouzioux C, HIV cure and eradication: how will we get from the laboratory to effective clinical trials?Aids. 2011;25(7):885–97. doi: 10.1097/QAD.0b013e3283467041ISI:000289458900001.
9. Williams JP, Hurst J, Stohr W, Robinson N, Brown H, Fisher M, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. eLife. 2014;3:e03821. doi: 10.7554/eLife.0382125217531; PubMed Central PMCID: PMC4199415.
10. Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, et al. Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis. 2013;207(2):213–22. doi: 10.1093/infdis/jis66323105144; PubMed Central PMCID: PMC3532820.
11. Sharkey M, Babic DZ, Greenough T, Gulick R, Kuritzkes DR, Stevenson M, Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure. PLoS pathogens. 2011;7(2). doi: ARTN e1001303 doi: 10.1371/journal.ppat.1001303WOS:000287698200041.
12. Eriksson S, Graf EH, Dahl V, Strain MC, Yukl SA, Lysenko ES, et al. Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS pathogens. 2013;9(2):e1003174. doi: 10.1371/journal.ppat.100317423459007; PubMed Central PMCID: PMC3573107.
13. Strain MC, Richman DD, New assays for monitoring residual HIV burden in effectively treated individuals. Current opinion in HIV and AIDS. 2013;8(2):106–10. doi: 10.1097/COH.0b013e32835d811b23314907; PubMed Central PMCID: PMC3754420.
14. Pasternak AO, Lukashov VV, Berkhout B, Cell-associated HIV RNA: a dynamic biomarker of viral persistence. Retrovirology. 2013;10:41. doi: 10.1186/1742-4690-10-4123587031; PubMed Central PMCID: PMC3637491.
15. Bland JM, Altman DG, Agreed statistics: measurement method comparison. Anesthesiology. 2012;116(1):182–5. Epub 2011/12/02. doi: 10.1097/ALN.0b013e31823d778422129533.
16. Buzon MJ, Martin-Gayo E, Pereyra F, Ouyang ZY, Sun H, Li JZ, et al. Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells. J Virol. 2014;88(17):10056–65. doi: 10.1128/Jvi.01046-14WOS:000341232300047.
17. De Spiegelaere W, Malatinkova E, Lynch L, Van Nieuwerburgh F, Messiaen P, O'Doherty U, et al. Quantification of Integrated HIV DNA by Repetitive-Sampling Alu-HIV PCR on the Basis of Poisson Statistics. Clin Chem. 2014;60(6):886–95. doi: 10.1373/clinchem.2013.219378WOS:000344778600015.
18. Graf EH, O'Doherty U, Quantitation of integrated proviral DNA in viral reservoirs. Current opinion in HIV and AIDS. 2013;8(2):100–5. doi: 10.1097/COH.0b013e32835d813223340051.
19. Siliciano JD, Siliciano RF, Recent developments in the search for a cure for HIV-1 infection: targeting the latent reservoir for HIV-1. J Allergy Clin Immunol. 2014;134(1):12–9. Epub 2014/08/15. doi: 10.1016/j.jaci.2014.05.026 S0091-6749(14)00739-8 [pii]. 25117799.
20. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, et al. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J Infect Dis. 2007;195(12):1762–4. doi: 10.1086/51825017492591.
21. Pace MJ, Graf EH, O'Doherty U, HIV 2-long terminal repeat circular DNA is stable in primary CD4+T Cells. Virology. 2013;441(1):18–21. doi: 10.1016/j.virol.2013.02.028ISI:000319180300003.
22. Sharkey M, Triques K, Kuritzkes DR, Stevenson M, In vivo evidence for instability of episomal human immunodeficiency virus type 1 cDNA. J Virol. 2005;79(8):5203–10. doi: 10.1128/Jvi.79.8.5203–5210.2005ISI:000228073700062.
23. Llibre JM, Buzon MJ, Massanella M, Esteve A, Dahl V, Puertas MC, et al. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study. Antiviral therapy. 2012;17(2):355–64. doi: 10.3851/IMP191722290239.
24. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences of the United States of America. 1997;94(24):13193–7. 9371822; PubMed Central PMCID: PMC24285.
25. Wagner TA, McLaughlin S, Garg K, Cheung CYK, Larsen BB, Styrchak S, et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. 2014;345(6196):570–3. doi: 10.1126/science.1256304WOS:000339651300047.
26. Chun TW, Murray D, Justement JS, Hallahan CW, Moir S, Kovacs C, et al. Relationship Between Residual Plasma Viremia and the Size of HIV Proviral DNA Reservoirs in Infected Individuals Receiving Effective Antiretroviral Therapy. J Infect Dis. 2011;204(1):135–8. doi: 10.1093/infdis/jir208WOS:000292561800018.
27. Carstensen B, Comparing methods of measurement: Extending the LoA by regression. Stat Med. 2010;29(3):401–10. Epub 2009/12/10. doi: 10.1002/sim.376919998394.
28. Saez-Cirion A, Bacchus C, Hocqueloux L, Avettand-Fenoel V, Girault I, Lecuroux C, et al. Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study. PLoS pathogens. 2013;9(3). doi: ARTN e1003211 doi: 10.1371/journal.ppat.1003211WOS:000316953800017.
29. Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. The Lancet HIV. 2014;1(1):e13–e21. doi: http://dx.doi.org/10.1016/S2352-3018(14)70014-1. 26423811
30. Laird GM, Eisele EE, Rabi SA, Lai J, Chioma S, Blankson JN, et al. Rapid Quantification of the Latent Reservoir for HIV-1 Using a Viral Outgrowth Assay. PLoS pathogens. 2013;9(5). doi: ARTN e1003398 doi: 10.1371/journal.ppat.1003398WOS:000320032800063.
31. Procopio FA, Fromentin R, Kulpa DA, Brehm JH, Bebin A, Strain MC, et al. A Novel Assay to Measure the Magnitude of the Inducible Viral Reservoir in HIV-infected Individuals. EBioMedicine. 2015. doi: 10.1016/j.ebiom.2015.06.019
32. Abdel-Mohsen M, Raposo RA, Deng X, Li M, Liegler T, Sinclair E, et al. Expression profile of host restriction factors in HIV-1 elite controllers. Retrovirology. 2013;10:106. doi: 10.1186/1742-4690-10-10624131498; PubMed Central PMCID: PMC3827935.
33. Goujon C, Moncorge O, Bauby H, Doyle T, Ward CC, Schaller T, et al. Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection. Nature. 2013;502(7472):559–+. doi: 10.1038/Nature12542WOS:000325988400056.
34. Kane M, Yadav SS, Bitzegeio J, Kutluay SB, Zang T, Wilson SJ, et al. MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature. 2013;502(7472):563–+. doi: 10.1038/Nature12653WOS:000325988400057.
35. Matreyek KA, Wang W, Serrao E, Singh PK, Levin HL, Engelman A, Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology. 2014;11:90. Epub 2014/10/29. doi: 10.1186/s12977-014-0090-zs12977-014-0090-z [pii]. 25348155; PubMed Central PMCID: PMC4213484.
36. Merindol N, Berthoux L, Restriction Factors in HIV-1 Disease Progression. Curr HIV Res. 2015;13(6):448–61. Epub 2015/06/09. doi: CHR-EPUB-67947 [pii]. 26051387.
37. Abdel-Mohsen M, Wang C, Strain MC, Lada SM, Deng X, Cockerham LR, et al. Select host restriction factors are associated with HIV persistence during antiretroviral therapy. Aids. 2015;29(4):411–20. doi: 10.1097/QAD.000000000000057225602681.
38. De Pasquale M, Kourteva Y, Allos T, D'Aquila RT, Lower HIV Provirus Levels Are Associated with More APOBEC3G Protein in Blood Resting Memory CD4+T Lymphocytes of Controllers In Vivo. PloS one. 2013;8(10). doi: ARTN e76002 doi: 10.1371/journal.pone.0076002WOS:000326019400030.
39. Kiselinova M, Geretti A, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. Journal of Antimicrobial Chemotherapy. 2015. Epub 2015/08/31. doi: 10.1093/jac/dkv250
40. Malatinkova E, Kiselinova M, Bonczkowski P, Trypsteen W, Messiaen P, Vermeire J, et al. Accurate quantification of episomal HIV-1 two-long terminal repeat circles by use of optimized DNA isolation and droplet digital PCR. J Clin Microbiol. 2015;53(2):699–701. doi: 10.1128/JCM.0308725502524
41. Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. J Antimicrob Chemother. 2015. doi: 10.1093/jac/dkv25026324076.
42. Malatinkova E, Spiegelaere W, Bonczkowski P, Kiselinova M, Vervisch K, Trypsteen W, et al. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. eLife. 2015;4. doi: 10.7554/eLife.0911526439007.
43. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002;3(7). doi: Artn 0034.1 doi: 10.1186/Gb-2002-3-7-Research0034WOS:000207581200010.
44. De Spiegelaere W, Dern-Wieloch J, Weigel R, Schumacher V, Schorle H, Nettersheim D, et al. Reference Gene Validation for RT-qPCR, a Note on Different Available Software Packages. PloS one. 2015;10(3):e0122515. doi: 10.1371/journal.pone.012251525825906.
45. Messiaen P, De Spiegelaere W, Alcami J, Vervisch K, Van Acker P, Verhasselt B, et al. Characterization of LEDGF/p75 Genetic Variants and Association with HIV-1 Disease Progression. PloS one. 2012;7(11). doi: ARTN e50204 doi: 10.1371/journal.pone.0050204WOS:000312376100056.
46. Hellemans J, Mortier G, De Paepe A, Speleman F, Vandesompele J, qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data. Genome Biol. 2007;8(2):R19. doi: 10.1186/gb-2007-8-2-r1917291332; PubMed Central PMCID: PMC1852402.